Literature DB >> 16385625

Solid tumors "melt" from the inside after successful CD8 T cell attack.

Ulrike Blohm1, Dan Potthoff, Albert J van der Kogel, Hanspeter Pircher.   

Abstract

Adoptive transfer of tumor-specific T cells represents a promising approach for cancer immunotherapy. Here, we visualized the anti-tumor response of CD8 T cells from P14 TCR-transgenic mice specific for the model antigen GP33 by immunohistology. P14 T cells, adoptively transferred into tumor-bearing hosts, induced regression of established 3LL-A9(GP33) and MCA102(GP33) tumors that express GP33 as a tumor-associated model antigen. Strikingly, the visible effects of P14 T cell attack, such as the destruction of the tumor vasculature and accumulation of granulocytes, were predominantly detected inside the tumor mass. In regressing tumors, P14 T cells were found in the intact rim zone but not in central areas that were infiltrated with granulocytes and lacked CD31(+) endothelial cells. The rim of P14 T cell-treated tumors showed an increase in vascular density and decrease in hypoxia compared to untreated tumors. Hypoxic areas of tumors are known to exhibit decreased sensitivity to radiation therapy or chemotherapy. Thus, our data also imply that adoptive transfer of tumor-specific CD8 T cells might synergize with radiation therapy or chemotherapy in the elimination of solid tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385625     DOI: 10.1002/eji.200526175

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.

Authors:  Alexandre Boissonnas; Luc Fetler; Ingrid S Zeelenberg; Stéphanie Hugues; Sebastian Amigorena
Journal:  J Exp Med       Date:  2007-01-29       Impact factor: 14.307

2.  Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Authors:  Kathleen Anders; Christian Buschow; Andreas Herrmann; Ana Milojkovic; Christoph Loddenkemper; Thomas Kammertoens; Peter Daniel; Hua Yu; Jehad Charo; Thomas Blankenstein
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

3.  Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Authors:  Béatrice Breart; Fabrice Lemaître; Susanna Celli; Philippe Bousso
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.

Authors:  Jodi L Yorty; Satvir S Tevethia; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2007-11-15       Impact factor: 6.968

5.  Trends in cancer immunotherapy.

Authors:  Joseph F Murphy
Journal:  Clin Med Insights Oncol       Date:  2010-07-14

6.  Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.

Authors:  C D Lemke; J B Graham; D M Lubaroff; A K Salem
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-01-25       Impact factor: 5.554

7.  Revisiting the role of T cells in tumor regression.

Authors:  Nadège Bercovici; Alain Trautmann
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

8.  Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Authors:  Andrea Schietinger; Ainhoa Arina; Rebecca B Liu; Sam Wells; Jianhua Huang; Boris Engels; Vytas Bindokas; Todd Bartkowiak; David Lee; Andreas Herrmann; David W Piston; Mikael J Pittet; P Charles Lin; Tomasz Zal; Hans Schreiber
Journal:  Oncoimmunology       Date:  2013-11-04       Impact factor: 8.110

9.  Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Authors:  Meriem Hasmim; Cécile Badoual; Philippe Vielh; Françoise Drusch; Virginie Marty; Agnès Laplanche; Mariana de Oliveira Diniz; Hélène Roussel; Eléonore De Guillebon; Stéphane Oudard; Stéphane Hans; Eric Tartour; Salem Chouaib
Journal:  BMC Cancer       Date:  2013-12-11       Impact factor: 4.430

10.  Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.

Authors:  Daniel O Villarreal; Diana Chin; Melissa A Smith; Leopoldo L Luistro; Linda A Snyder
Journal:  Oncotarget       Date:  2017-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.